VX-264
Phase 2Small molecule
Vertex PharmaceuticalsVX-264 is one of 60 small molecule programs targeting Duchenne Muscular Dystrophy. It is currently in Phase 2.
2
Indications
1
Total Trials
1
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
384 competitors in Type 1 Diabetes
#DrugCompanyPhaseTrials
1Symlin
AstraZenecaPreclinical
Symlin
AstraZenecaPreclinical
Aldomet
Neurocrine BiosciencesPreclinical
VX-264
Vertex PharmaceuticalsPhase 2
Pitocin
RRetrophin
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Cytoxan
BBaxter Healthcare Corporation
Preclinical
Foradil
ViatrisPreclinical
Glargine
Eli LillyPreclinical
SGLT2 Inhibitor
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VX-264. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company